US Stock MarketDetailed Quotes

GDTC CytoMed Therapeutics

Watchlist
  • 2.797
  • +0.217+8.41%
Close Dec 26 16:00 ET
32.28MMarket Cap-13.91P/E (TTM)

CytoMed Therapeutics Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(FY)Dec 31, 2022
(FY)Dec 31, 2021
(FY)Dec 31, 2020
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-145.48%-3.43M
18.36%-1.4M
-101.66%-1.71M
-849.44K
Net income from continuing operations
-32.04%-4.13M
-52.53%-3.13M
-6.01%-2.05M
---1.94M
Operating gains losses
2,075.11%252.51K
-95.75%11.61K
31,046.55%273.26K
---883
Depreciation and amortization
-2.98%381.15K
19.09%392.87K
12.77%329.88K
--292.53K
Other non cash items
-290.48%-234.44K
7.65%123.08K
8.35%114.33K
--105.52K
Change In working capital
-4.53%104.92K
129.76%109.9K
-419.44%-369.25K
--115.59K
-Change in receivables
96.38%-5.26K
66.48%-145.17K
-167.27%-433.12K
---162.05K
-Change in payables and accrued expense
-56.81%110.18K
299.37%255.07K
-77.00%63.87K
--277.64K
Cash from discontinued investing activities
Operating cash flow
-145.48%-3.43M
18.36%-1.4M
-101.66%-1.71M
---849.44K
Investing cash flow
Cash flow from continuing investing activities
-497.75%-2.83M
42.54%-473.31K
-60.54%-823.67K
-513.05K
Net PPE purchase and sale
87.68%-58.3K
18.73%-473.31K
-137.96%-582.35K
---244.73K
Net intangibles purchase and sale
----
----
----
---20.43K
Net business purchase and sale
--0
--0
---241.31K
--0
Net investment purchase and sale
---2.77M
--0
--0
---247.9K
Cash from discontinued investing activities
Investing cash flow
-497.75%-2.83M
42.54%-473.31K
-60.54%-823.67K
---513.05K
Financing cash flow
Cash flow from continuing financing activities
1,027.25%10.92M
-76.79%968.72K
121.57%4.17M
1.88M
Net issuance payments of debt
-164.39%-340.43K
-144.23%-128.76K
-80.45%291.09K
--1.49M
Net common stock issuance
824.80%11.31M
-38.87%1.22M
300.00%2M
--500K
Cash dividends paid
--0
--0
--0
--0
Net other financing activities
----
----
--2M
----
Cash from discontinued financing activities
Financing cash flow
1,027.25%10.92M
-76.79%968.72K
121.57%4.17M
--1.88M
Net cash flow
Beginning cash position
-37.13%1.58M
183.84%2.51M
138.66%885.27K
--370.94K
Current changes in cash
615.82%4.66M
-155.17%-903K
214.14%1.64M
--521.03K
Effect of exchange rate changes
55.37%-13.41K
-224.92%-30.05K
-38.15%-9.25K
---6.7K
End cash Position
294.01%6.22M
-37.13%1.58M
183.84%2.51M
--885.27K
Free cash flow
-86.47%-3.49M
18.43%-1.87M
-105.93%-2.3M
---1.11M
Currency Unit
SGD
SGD
SGD
SGD
Audit Opinions
Unqualified Opinion
Unqualified Opinion
--
--
(FY)Dec 31, 2023(FY)Dec 31, 2022(FY)Dec 31, 2021(FY)Dec 31, 2020
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -145.48%-3.43M18.36%-1.4M-101.66%-1.71M-849.44K
Net income from continuing operations -32.04%-4.13M-52.53%-3.13M-6.01%-2.05M---1.94M
Operating gains losses 2,075.11%252.51K-95.75%11.61K31,046.55%273.26K---883
Depreciation and amortization -2.98%381.15K19.09%392.87K12.77%329.88K--292.53K
Other non cash items -290.48%-234.44K7.65%123.08K8.35%114.33K--105.52K
Change In working capital -4.53%104.92K129.76%109.9K-419.44%-369.25K--115.59K
-Change in receivables 96.38%-5.26K66.48%-145.17K-167.27%-433.12K---162.05K
-Change in payables and accrued expense -56.81%110.18K299.37%255.07K-77.00%63.87K--277.64K
Cash from discontinued investing activities
Operating cash flow -145.48%-3.43M18.36%-1.4M-101.66%-1.71M---849.44K
Investing cash flow
Cash flow from continuing investing activities -497.75%-2.83M42.54%-473.31K-60.54%-823.67K-513.05K
Net PPE purchase and sale 87.68%-58.3K18.73%-473.31K-137.96%-582.35K---244.73K
Net intangibles purchase and sale ---------------20.43K
Net business purchase and sale --0--0---241.31K--0
Net investment purchase and sale ---2.77M--0--0---247.9K
Cash from discontinued investing activities
Investing cash flow -497.75%-2.83M42.54%-473.31K-60.54%-823.67K---513.05K
Financing cash flow
Cash flow from continuing financing activities 1,027.25%10.92M-76.79%968.72K121.57%4.17M1.88M
Net issuance payments of debt -164.39%-340.43K-144.23%-128.76K-80.45%291.09K--1.49M
Net common stock issuance 824.80%11.31M-38.87%1.22M300.00%2M--500K
Cash dividends paid --0--0--0--0
Net other financing activities ----------2M----
Cash from discontinued financing activities
Financing cash flow 1,027.25%10.92M-76.79%968.72K121.57%4.17M--1.88M
Net cash flow
Beginning cash position -37.13%1.58M183.84%2.51M138.66%885.27K--370.94K
Current changes in cash 615.82%4.66M-155.17%-903K214.14%1.64M--521.03K
Effect of exchange rate changes 55.37%-13.41K-224.92%-30.05K-38.15%-9.25K---6.7K
End cash Position 294.01%6.22M-37.13%1.58M183.84%2.51M--885.27K
Free cash flow -86.47%-3.49M18.43%-1.87M-105.93%-2.3M---1.11M
Currency Unit SGDSGDSGDSGD
Audit Opinions Unqualified OpinionUnqualified Opinion----
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.